169 related articles for article (PubMed ID: 29296211)
1. Global lipidomics identified plasma lipids as novel biomarkers for early detection of lung cancer.
Yu Z; Chen H; Ai J; Zhu Y; Li Y; Borgia JA; Yang JS; Zhang J; Jiang B; Gu W; Deng Y
Oncotarget; 2017 Dec; 8(64):107899-107906. PubMed ID: 29296211
[TBL] [Abstract][Full Text] [Related]
2. Global lipidomics reveals two plasma lipids as novel biomarkers for the detection of squamous cell lung cancer: A pilot study.
Yu Z; Chen H; Zhu Y; Ai J; Li Y; Gu W; Borgia JA; Zhang J; Jiang B; Chen W; Deng Y
Oncol Lett; 2018 Jul; 16(1):761-768. PubMed ID: 29963143
[TBL] [Abstract][Full Text] [Related]
3. Screening and identification of potential novel lipid biomarkers for non-small cell lung cancer using ultra-high performance liquid chromatography tandem mass spectrometry.
Han YS; Shi LY; Chen JX; Chen J; Li ZB; Lu QQ; Zhang SQ; Liu J; Yi WJ; Jiang TT; Li JC; Huang J
Anat Rec (Hoboken); 2022 May; 305(5):1087-1099. PubMed ID: 34347376
[TBL] [Abstract][Full Text] [Related]
4. Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Chen X; Chen H; Dai M; Ai J; Li Y; Mahon B; Dai S; Deng Y
Oncotarget; 2016 Jun; 7(24):36622-36631. PubMed ID: 27153558
[TBL] [Abstract][Full Text] [Related]
5. Application of Lipidomics for Assessing Tissue Lipid Profiles of Patients With Squamous Cell Carcinoma.
Zeng W; Zheng W; Hu S; Zhang J; Zhang W; Xu J; Yu D; Peng J; Zhang L; Gong M; Wei Y
Technol Cancer Res Treat; 2021; 20():15330338211049903. PubMed ID: 34761720
[No Abstract] [Full Text] [Related]
6. Identification of potential lipid biomarkers for active pulmonary tuberculosis using ultra-high-performance liquid chromatography-tandem mass spectrometry.
Han YS; Chen JX; Li ZB; Chen J; Yi WJ; Huang H; Wei LL; Jiang TT; Li JC
Exp Biol Med (Maywood); 2021 Feb; 246(4):387-399. PubMed ID: 33175608
[TBL] [Abstract][Full Text] [Related]
7. A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer.
Cheng F; Wen Z; Feng X; Wang X; Chen Y
Life Sci; 2020 Nov; 260():118489. PubMed ID: 32976882
[TBL] [Abstract][Full Text] [Related]
8. Serum lipidomic biomarkers for non-small cell lung cancer in nonsmoking female patients.
Noreldeen HAA; Du L; Li W; Liu X; Wang Y; Xu G
J Pharm Biomed Anal; 2020 Jun; 185():113220. PubMed ID: 32145537
[TBL] [Abstract][Full Text] [Related]
9. Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening.
Dou Y; Zhu Y; Ai J; Chen H; Liu H; Borgia JA; Li X; Yang F; Jiang B; Wang J; Deng Y
BMC Genomics; 2018 Jul; 19(1):545. PubMed ID: 30029594
[TBL] [Abstract][Full Text] [Related]
10. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.
Geng Q; Fan T; Zhang B; Wang W; Xu Y; Hu H
Respir Res; 2014 Nov; 15(1):149. PubMed ID: 25421010
[TBL] [Abstract][Full Text] [Related]
11. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics.
Zhou X; Mao J; Ai J; Deng Y; Roth MR; Pound C; Henegar J; Welti R; Bigler SA
PLoS One; 2012; 7(11):e48889. PubMed ID: 23152813
[TBL] [Abstract][Full Text] [Related]
12. LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma.
Liu X; Zhang M; Cheng X; Liu X; Sun H; Guo Z; Li J; Tang X; Wang Z; Sun W; Zhang Y; Ji Z
Front Oncol; 2020; 10():717. PubMed ID: 32500026
[TBL] [Abstract][Full Text] [Related]
13. UPLC-MS/MS-based plasma lipidomics reveal a distinctive signature in systemic lupus erythematosus patients.
Chen J; Liu C; Ye S; Lu R; Zhu H; Xu J
MedComm (2020); 2021 Jun; 2(2):269-278. PubMed ID: 34766146
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis.
Wang G; Qiu M; Xing X; Zhou J; Yao H; Li M; Yin R; Hou Y; Li Y; Pan S; Huang Y; Yang F; Bai F; Nie H; Di S; Guo L; Meng Z; Wang J; Yin Y
Sci Transl Med; 2022 Feb; 14(630):eabk2756. PubMed ID: 35108060
[TBL] [Abstract][Full Text] [Related]
15. Plasma lipidomic profiles of kidney, breast and prostate cancer patients differ from healthy controls.
Wolrab D; Jirásko R; Peterka O; Idkowiak J; Chocholoušková M; Vaňková Z; Hořejší K; Brabcová I; Vrána D; Študentová H; Melichar B; Holčapek M
Sci Rep; 2021 Oct; 11(1):20322. PubMed ID: 34645896
[TBL] [Abstract][Full Text] [Related]
16. Serum lipid profile discriminates patients with early lung cancer from healthy controls.
Ros-Mazurczyk M; Jelonek K; Marczyk M; Binczyk F; Pietrowska M; Polanska J; Dziadziuszko R; Jassem J; Rzyman W; Widlak P
Lung Cancer; 2017 Oct; 112():69-74. PubMed ID: 29191603
[TBL] [Abstract][Full Text] [Related]
17. Potential circulating miRNA signature for early detection of NSCLC.
Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
[TBL] [Abstract][Full Text] [Related]
18. Decreased sphingomyelin (t34:1) is a candidate predictor for lung squamous cell carcinoma recurrence after radical surgery: a case-control study.
Takanashi Y; Funai K; Eto F; Mizuno K; Kawase A; Tao H; Kitamoto T; Takahashi Y; Sugimura H; Setou M; Kahyo T; Shiiya N
BMC Cancer; 2021 Nov; 21(1):1232. PubMed ID: 34789180
[TBL] [Abstract][Full Text] [Related]
19. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer.
Zhong L; Coe SP; Stromberg AJ; Khattar NH; Jett JR; Hirschowitz EA
J Thorac Oncol; 2006 Jul; 1(6):513-9. PubMed ID: 17409910
[TBL] [Abstract][Full Text] [Related]
20. Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer.
Zhang H; Mao F; Shen T; Luo Q; Ding Z; Qian L; Huang J
Oncol Lett; 2017 Feb; 13(2):669-676. PubMed ID: 28356944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
